Amicus Therapeutics (FOLD) CPO equity fully cashed out at $14.50 deal price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics’ Chief People Officer David Michael Clark disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 221,811 shares of Common Stock were surrendered at $14.50 per share, including 130,942 shares and 90,869 restricted stock units that vested at closing.
Multiple fully vested stock option grants covering tens of thousands of shares each were cancelled and converted into cash. For each option, Clark became entitled to a cash payment equal to the excess of $14.50 over the option’s exercise price, multiplied by the shares subject to that option. Following these transactions, the Form 4 reports zero remaining direct holdings.
Positive
- None.
Negative
- None.
Insights
All of the CPO’s Amicus equity was cashed out at merger close.
The Form 4 shows David Michael Clark, Chief People Officer of Amicus Therapeutics, disposing of Common Stock, restricted stock units, and multiple fully vested stock option grants when BioMarin’s acquisition of Amicus was consummated at $14.50 per share.
Rather than open‑market trading, these are mechanical merger-related transactions: shares and options were surrendered to the issuer and converted into cash consideration based on the $14.50 deal price and each option’s exercise price. The filing reports zero remaining direct holdings, consistent with a full equity cash-out at closing.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Clark David Michael
Role
Chief People Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 84,842 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 77,134 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 91,439 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 108,266 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 105,388 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 83,221 | $0.00 | -- |
| Disposition | Stock Options (right to buy) | 125,430 | $0.00 | -- |
| Disposition | Common Stock | 221,811 | $14.50 | $3.22M |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 130,942 shares of Common Stock and 90,869 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common Stock disposed: 221,811 shares at $14.50
Common shares component: 130,942 shares
Restricted stock units vested: 90,869 RSUs
+5 more
8 metrics
Common Stock disposed
221,811 shares at $14.50
Surrendered in connection with BioMarin merger
Common shares component
130,942 shares
Part of 221,811 shares surrendered at merger close
Restricted stock units vested
90,869 RSUs
Vested in full upon consummation of the merger
Option grant size
125,430 options at $9.41
Fully vested option cancelled for cash based on $14.50 price
Option grant size
83,221 options at $14.24
Fully vested option cancelled and paid in cash at closing
Option grant size
105,388 options at $11.93
Fully vested option cancelled for cash at merger
Option grant size
108,266 options at $12.11
Fully vested option cancelled for cash at merger
Option grant size
91,439 options at $9.55
Fully vested option cancelled for cash at merger
Key Terms
restricted stock units, Merger, stock option, exercise price, +1 more
5 terms
restricted stock units financial
"which included 130,942 shares of Common Stock and 90,869 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Merger financial
"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"Each Option was fully vested."
FAQ
What did Amicus Therapeutics (FOLD) report in this Form 4 for David Michael Clark?
The Form 4 reports that Chief People Officer David Michael Clark disposed of all reported Amicus equity in connection with BioMarin’s acquisition, surrendering Common Stock, restricted stock units, and vested stock options for cash tied to the $14.50-per-share merger price.
What happened to David Michael Clark’s Amicus stock options in the BioMarin merger?
Each reported Amicus stock option was cancelled at closing and converted into a cash payment. The payment equals the excess of the $14.50 merger price over the option’s exercise price, multiplied by the number of shares subject to that option, with each option fully vested at consummation.
Does David Michael Clark retain any Amicus Therapeutics holdings after the BioMarin deal?
The Form 4 reports zero shares and options remaining after the merger-related dispositions. Common Stock, restricted stock units, and multiple fully vested option grants were cancelled or surrendered and converted into cash as part of BioMarin’s acquisition of Amicus Therapeutics.